B. Tian, A. Qin, Z.Y. Shao, T. Jiang, Z.J. Zhai, H.W. Li, T.T. Tang, Q. Jiang, K.R. Dai, M.H. Zheng, Y.P. Yu and Z.A. Zhu Pages 641 - 649 ( 9 )
Osteoclasts are one of the key therapeutic targets for a variety of orthopedic diseases such as osteoporosis and osteoarthritis. In this study, we synthesized a novel compound N-(3-(cyclohexylcarbamoyl) phenyl)-1H-indole-2- carboxamide (termed as OA-4) and investigated the effects of OA-4 on the differentiation and function of osteoclasts. OA-4 markedly diminished osteoclast differentiation and osteoclast specific gene expression in a dose-dependent manner. In addition, OA-4 dose-dependently suppressed osteoclastic bone resorption. Furthermore, we found OA-4 attenuated RANKL-induced p38 phosphorylation without affecting JNK or NF-κB signaling pathways. Collectively, we synthesized a novel compound OA-4 which can inhibit osteoclast formation and functions via the suppression of p38 signaling pathway.
OA-4, osteoclast formation, osteoclastic bone resorption, osteoporosis, P38 signaling pathway.
, , , , , , , , , , , Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedics, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, The People's Republic of China, Address: 639 Zhizaoju Road, Shanghai 200011, P.R.China.